BOCA RATON, Fla., June 28 /PRNewswire/ -- NovaVision today announced the appointment of Mark Testerman as the company's vice president of sales and marketing for the United States. In his new role, Testerman is responsible for overall sales and marketing strategy as well the company's growing relationships with leading neurological, eye and rehabilitation centers nationwide.
Testerman assumes his new post after holding several senior level sales and marketing positions in both the start-up environment as well as with major corporations. He most recently co-founded Alimera Sciences, an Alpharetta, Ga.-based ophthalmic pharmaceutical company where he spearheaded the development of the existing product portfolio and hired a specialty sales organization. He was also vice president of sales at Novartis Opthalmics, building national sales and marketing teams and overseeing a 100-person-strong sales department in field sales, operations, managed care and distribution.
"Mark has a long and solid history of marketing vision-focused therapies, and based on his expertise he is the ideal executive to elevate visibility for NovaVision Vision Restoration Therapy," said Navroze Mehta, NovaVision President and CEO. "His proven success in building effective sales organizations as well as his knowledge of the healthcare marketplace will benefit NovaVision tremendously as the company grows its presence."
Currently, NovaVision VRT is offered in nearly 50 centers across the United States and the company expects to increase this amount in the short- term future.
NovaVision VRT is the first and only FDA-cleared, patented, non-invasive medical device that can enhance vision in people who have been left partially blind due to stroke or brain trauma. Treatment consists of comprehensive diagnostic testing that maps the seeing and non-seeing areas of vision and creates a customized therapy that participants perform daily at home for six to seven months. Patients gradually improve their vision through the repeated detection of light stimuli directed at the border between the seeing and blind areas of the visual field.
Through its proven therapy, NovaVision provides hope to the approximately 1 to 2 million stroke and brain injury survivors in the United States who suffer from major visual field deficits, a number that increases by more than 90,000 each year.
About NovaVision, Inc.
NovaVision, Inc., headquartered in Boca Raton, Fla., develops and provides scientifically based, innovative medical devices and comprehensive solutions to restore the vision of patients with neurological visual impairments. NovaVision's FDA-cleared NovaVisionVRT(TM) (VRT) is based on neuroplasticity - - the brain's ability to adapt and form new connections to compensate for injury. NovaVision diagnostic testing maps areas where vision may be improved, and therapy targets and stimulates regions within the brain's vision-processing areas.
VRT is based on more than 10 years of research with clinical studies published in leading journals including Nature Medicine, Neurology, and The Journal of Cognitive Neuroscience. Data from a recent retrospective study identified that more than 70 percent of U.S. patients who underwent NovaVision VRT for an initial six-month treatment period showed significant improvement in their vision.
More than 1,000 stroke and traumatic brain injury patients have been treated with NovaVision VRT and clinical results are positive. NovaVision VRT is currently offered at 50 leading neurological, eye and rehabilitation centers nationwide. For more information and a list of centers offering NovaVision VRT, please visit www.novavision.com or call 888.205.0800.
Contact: Ellie Kline, Edelman on behalf of NovaVision Ph. 212-704-4528 Email: elinor.kline@edelman.com
NovaVisionCONTACT: Ellie Kline of Edelman, +1-212-704-4528,elinor.kline@edelman.com, for NovaVision
Web site: http://www.novavision.com/
